Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae

BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae is a leading cause of life-threatening sepsis in newborns1 as well as healthcare-associated infections, including pneumonia, bloodstream infec